Next Article in Journal
Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson’s Disease
Previous Article in Journal
Polyphenol and Tannin Nutraceuticals and Their Metabolites: How the Human Gut Microbiota Influences Their Properties
 
 
Article

Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study

1
The Biotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, WA 6102, Australia
2
Hearing Therapeutics Department, Ear Science Institute Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, WA 6009, Australia
3
Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Hajduk Veljkova 3, 21101 Novi Sad, Serbia
*
Author to whom correspondence should be addressed.
Academic Editor: Jorge Joven
Biomolecules 2022, 12(7), 877; https://doi.org/10.3390/biom12070877
Received: 11 April 2022 / Revised: 15 June 2022 / Accepted: 22 June 2022 / Published: 23 June 2022
Recent preclinical studies in our laboratory have shown that the bile acid profile is altered during diabetes development and such alteration has been linked to the diabetes-associated inflammatory profile. Hence, this study aimed to investigate if the first-line antidiabetic drug metformin will alter the bile acid profile and diabetes-associated inflammation in a murine model of pre-type 2 diabetes. C57 mice were randomly allocated into three equal groups of eight. Group One was given a low-fat diet (LFD), Group Two was given a high-fat diet (HFD), and Group Three was given an HFD and, upon prediabetes confirmation, daily oral metformin for one month. Blood glucose, glycated haemoglobin, drug concentrations in tissues and faeces, and the inflammatory and bile acid profiles were measured. Metformin showed wide tissue distribution and was also present in faeces. The bile acid profile showed significant alteration due to prediabetes, and although metformin did not completely normalize it, it did exert significant effects on both the bile acid and the inflammatory profiles, suggesting a direct and, to some extent, positive impact, particularly on the diabetes-associated inflammatory profile. View Full-Text
Keywords: diabetes mellitus; bile acids; inflammation; cytokines; interleukins diabetes mellitus; bile acids; inflammation; cytokines; interleukins
Show Figures

Graphical abstract

MDPI and ACS Style

Mooranian, A.; Chester, J.; Johnston, E.; Ionescu, C.M.; Walker, D.; Jones, M.; Wagle, S.R.; Kovacevic, B.; Foster, T.; Mikov, M.; Al-Salami, H. Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study. Biomolecules 2022, 12, 877. https://doi.org/10.3390/biom12070877

AMA Style

Mooranian A, Chester J, Johnston E, Ionescu CM, Walker D, Jones M, Wagle SR, Kovacevic B, Foster T, Mikov M, Al-Salami H. Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study. Biomolecules. 2022; 12(7):877. https://doi.org/10.3390/biom12070877

Chicago/Turabian Style

Mooranian, Armin, Jacqueline Chester, Edan Johnston, Corina Mihaela Ionescu, Daniel Walker, Melissa Jones, Susbin Raj Wagle, Bozica Kovacevic, Thomas Foster, Momir Mikov, and Hani Al-Salami. 2022. "Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study" Biomolecules 12, no. 7: 877. https://doi.org/10.3390/biom12070877

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop